Skip to main content

Intensive Care Management of Patients with Cirrhosis

  • Chapter
  • First Online:
  • 954 Accesses

Abstract

Patients with cirrhosis are at high risk of disease-associated complications. Hospitalized patients often present with multisystem organ dysfunction and failure and the need for intensive care unit support. Patients with cirrhosis presenting to the intensive care unit have high mortality rates approaching 50%. Common complications of cirrhosis that are present in the intensive care unit include abnormalities in neurological function, pulmonary and cardiovascular function, and disorders of hemostasis. Prompt identification of potential inciting events and aggressive supportive care is imperative to ensure the best outcome for this patient population. Prognosis is guided by the response of failing organ systems to supportive care. The definitive treatment of the complications associated with advanced liver disease remains liver transplantation, where demand outpaces organ availability.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Cordoba J, Ventura-Cots M, Simon-Talero M, Amoros A, Pavesi M, Vilstrup H, et al. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J Hepatol. 2014;60(2):275–81.

    Article  PubMed  Google Scholar 

  2. Nadim MK, Durand F, Kellum JA, Levitsky J, O’Leary JG, Karvellas CJ, et al. Management of the critically ill patient with cirrhosis: a multidisciplinary perspective. J Hepatol. 2016;64(3):717–35.

    Article  PubMed  Google Scholar 

  3. Cadranel JF, Lebiez E, Di Martino V, Bernard B, El Koury S, Tourbah A, et al. Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity? Am J Gastroenterol. 2001;96(2):515–8.

    Article  CAS  PubMed  Google Scholar 

  4. Rahimi RS, Rockey DC. Overuse of head computed tomography in cirrhosis with altered mental status. Am J Med Sci. 2016;351(5):459–66.

    Article  PubMed  Google Scholar 

  5. Strauss E, da Costa MF. The importance of bacterial infections as precipating factors of chronic hepatic encephalopathy in cirrhosis. Hepatogastroenterology. 1998;45(21):900–4.

    CAS  PubMed  Google Scholar 

  6. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–35.

    Article  PubMed  Google Scholar 

  7. Haj M, Rockey DC. Lactulose-induced hypernatremia in patients with hepatic encephalopathy. Hepatology. 2017;66(1 Suppl):277A–8A.

    Google Scholar 

  8. Haj M, Totin L, Rockey DC. Rectal or oral lactulose in patients admitted with hepatic encephalopathy. Hepatology. 2017;66(1 Suppl):279A–80A.

    Google Scholar 

  9. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–81.

    Article  CAS  PubMed  Google Scholar 

  10. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108(9):1458–63.

    Article  CAS  PubMed  Google Scholar 

  11. van der Spoel JI, Oudemans-van Straaten HM, Kuiper MA, van Roon EN, Zandstra DF, van der Voort PH. Laxation of critically ill patients with lactulose or polyethylene glycol: a two-center randomized, double-blind, placebo-controlled trial. Crit Care Med. 2007;35(12):2726–31.

    PubMed  Google Scholar 

  12. Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med. 2014;174(11):1727–33.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Shehata HH, Elfert AA, Abdin AA, Soliman SM, Elkhouly RA, Hawash NI, et al. Randomized controlled trial of polyethylene glycol versus lactulose for the treatment of overt hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2018;30(12):1476–81.

    Article  CAS  PubMed  Google Scholar 

  14. Naderian M, et al. Middle East J Dig Dis. 2017;9(1):12–9.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Bakti G, Fisch HU, Karlaganis G, Minder C, Bircher J. Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam. Hepatology. 1987;7(4):629–38.

    Article  CAS  PubMed  Google Scholar 

  16. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342(18):1301–8.

    Google Scholar 

  17. Maluso P, Olson J, Sarani B. Abdominal compartment hypertension and abdominal compartment syndrome. Crit Care Clin. 2016;32(2):213–22.

    Article  PubMed  Google Scholar 

  18. Umgelter A, Reindl W, Franzen M, Lenhardt C, Huber W, Schmid RM. Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites. Intensive Care Med. 2009;35(1):152–6.

    Article  CAS  PubMed  Google Scholar 

  19. Savino JA, Cerabona T, Agarwal N, Byrne D. Manipulation of ascitic fluid pressure in cirrhotics to optimize hemodynamic and renal function. Ann Surg. 1988;208(4):504–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Schenk P, Fuhrmann V, Madl C, Funk G, Lehr S, Kandel O, et al. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut. 2002;51(6):853–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Luo B, Liu L, Tang L, Zhang J, Stockard CR, Grizzle WE, et al. Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepatopulmonary syndrome. J Hepatol. 2003;38(5):556–63.

    Article  CAS  PubMed  Google Scholar 

  22. Nunes H, Lebrec D, Mazmanian M, Capron F, Heller J, Tazi KA, et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med. 2001;164(5):879–85.

    Article  CAS  PubMed  Google Scholar 

  23. Yang W, Zhang J, Hu B, Wu W, Venter J, Alpini G, et al. The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome. Am J Physiol Gastrointest Liver Physiol. 2014;306(1):G72–80.

    Article  CAS  PubMed  Google Scholar 

  24. Zhang J, Ling Y, Luo B, Tang L, Ryter SW, Stockard CR, et al. Analysis of pulmonary heme oxygenase-1 and nitric oxide synthase alterations in experimental hepatopulmonary syndrome. Gastroenterology. 2003;125(5):1441–51.

    Article  CAS  PubMed  Google Scholar 

  25. Zhang J, Luo B, Tang L, Wang Y, Stockard CR, Kadish I, et al. Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome. Gastroenterology. 2009;136(3):1070–80.

    Article  CAS  PubMed  Google Scholar 

  26. Zhang M, Luo B, Chen SJ, Abrams GA, Fallon MB. Endothelin-1 stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome. Am J Physiol. 1999;277(5):G944–52.

    CAS  PubMed  Google Scholar 

  27. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology. 2006;44(6):1502–10.

    Article  PubMed  Google Scholar 

  28. Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest. 2003;123(2):562–76.

    Article  PubMed  Google Scholar 

  29. Maruyama T, Ohsaki K, Shimoda S, Kaji Y, Harada M. Thromboxane-dependent portopulmonary hypertension. Am J Med. 2005;118(1):93–4.

    Article  CAS  PubMed  Google Scholar 

  30. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 2001;120(5):1562–9.

    Article  CAS  PubMed  Google Scholar 

  31. Wiest R, Groszmann RJ. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis. 1999;19(4):411–26.

    Article  CAS  PubMed  Google Scholar 

  32. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43(2 Suppl 1):S121–31.

    Article  CAS  PubMed  Google Scholar 

  33. Ruiz-del-Arbol L, Achecar L, Serradilla R, Rodriguez-Gandia MA, Rivero M, Garrido E, et al. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine. Hepatology. 2013;58(5):1732–41.

    Article  CAS  PubMed  Google Scholar 

  34. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22(2):107–33.

    Article  PubMed  Google Scholar 

  35. Sampaio F, Pimenta J, Bettencourt N, Fontes-Carvalho R, Silva AP, Valente J, et al. Systolic and diastolic dysfunction in cirrhosis: a tissue-Doppler and speckle tracking echocardiography study. Liver Int. 2013;33(8):1158–65.

    Article  CAS  PubMed  Google Scholar 

  36. Biancofiore G, Critchley LA, Lee A, Yang XX, Bindi LM, Esposito M, et al. Evaluation of a new software version of the FloTrac/Vigileo (version 3.02) and a comparison with previous data in cirrhotic patients undergoing liver transplant surgery. Anesth Analg. 2011;113(3):515–22.

    PubMed  Google Scholar 

  37. Sterling SA, Puskarich MA, Jones AE. The effect of liver disease on lactate normalization in severe sepsis and septic shock: a cohort study. Clin Exp Emerg Med. 2015;2(4):197–202.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002;36(4 Pt 1):941–8.

    Article  CAS  PubMed  Google Scholar 

  39. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology. 2002;36(2):374–80.

    Article  CAS  PubMed  Google Scholar 

  40. Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol. 2013;11(2):123–30 e1.

    Article  CAS  PubMed  Google Scholar 

  41. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403–9.

    Article  CAS  PubMed  Google Scholar 

  42. Fernandez J, Escorsell A, Zabalza M, Felipe V, Navasa M, Mas A, et al. Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatology. 2006;44(5):1288–95.

    Article  CAS  PubMed  Google Scholar 

  43. Sanchez W, Kamath PS. Managing septic shock in patients with cirrhosis: the role of adrenal insufficency. Gastroenterology. 2007;133(5):1733–4.

    Article  PubMed  Google Scholar 

  44. Tsai MH, Peng YS, Chen YC, Liu NJ, Ho YP, Fang JT, et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology. 2006;43(4):673–81.

    Article  PubMed  Google Scholar 

  45. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ. 2004;329(7464):480.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116(6):878–85.

    Article  CAS  PubMed  Google Scholar 

  47. Lisman T, Stravitz RT. Rebalanced hemostasis in patients with acute liver failure. Semin Thromb Hemost. 2015;41(5):468–73.

    Article  CAS  PubMed  Google Scholar 

  48. Smalberg JH, Leebeek FW. Superimposed coagulopathic conditions in cirrhosis: infection and endogenous heparinoids, renal failure, and endothelial dysfunction. Clin Liver Dis. 2009;13(1):33–42.

    Article  PubMed  Google Scholar 

  49. Youssef WI, Salazar F, Dasarathy S, Beddow T, Mullen KD. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol. 2003;98(6):1391–4.

    Article  PubMed  Google Scholar 

  50. Khan H, Belsher J, Yilmaz M, Afessa B, Winters JL, Moore SB, et al. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest. 2007;131(5):1308–14.

    Article  PubMed  Google Scholar 

  51. Li G, Rachmale S, Kojicic M, Shahjehan K, Malinchoc M, Kor DJ, et al. Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients. Transfusion. 2011;51(2):338–43.

    Article  PubMed  Google Scholar 

  52. Looney MR, Roubinian N, Gajic O, Gropper MA, Hubmayr RD, Lowell CA, et al. Prospective study on the clinical course and outcomes in transfusion-related acute lung injury∗. Crit Care Med. 2014;42(7):1676–87.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Toy P, Gajic O, Bacchetti P, Looney MR, Gropper MA, Hubmayr R, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood. 2012;119(7):1757–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol. 2007;138(4):534–40.

    Article  CAS  PubMed  Google Scholar 

  55. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44(1):53–61.

    Article  CAS  PubMed  Google Scholar 

  56. Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion. 2014;54(5):1389–405; quiz 8.

    Article  CAS  PubMed  Google Scholar 

  57. Nascimento B, Goodnough LT, Levy JH. Cryoprecipitate therapy. Br J Anaesth. 2014;113(6):922–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Spahn DR, Bouillon B, Cerny V, Duranteau J, Filipescu D, Hunt BJ, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care. 2019;23(1):98.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, Aracil C, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368(1):11–21.

    Article  CAS  PubMed  Google Scholar 

  60. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg. 1999;88(2):312–9.

    CAS  PubMed  Google Scholar 

  61. Alamo JM, Leon A, Mellado P, Bernal C, Marin LM, Cepeda C, et al. Is “intra-operating room” thromboelastometry useful in liver transplantation? A case-control study in 303 patients. Transplant Proc. 2013;45(10):3637–9.

    Article  PubMed  Google Scholar 

  62. De Pietri L, Bianchini M, Montalti R, De Maria N, Di Maira T, Begliomini B, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: a randomized, controlled trial. Hepatology. 2016;63(2):566–73.

    Article  PubMed  Google Scholar 

  63. Wu H, Nguyen GC. Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. Clin Gastroenterol Hepatol. 2010;8(9):800–5.

    Article  PubMed  Google Scholar 

  64. Gulley D, Teal E, Suvannasankha A, Chalasani N, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci. 2008;53(11):3012–7.

    Article  PubMed  Google Scholar 

  65. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54(5):691–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143(5):1253–60.e4.

    Article  CAS  PubMed  Google Scholar 

  67. Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology. 2015;62(1):243–52.

    Article  PubMed  Google Scholar 

  68. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426–37, 37.e1–9.

    Article  PubMed  Google Scholar 

  69. Karvellas CJ, Garcia-Lopez E, Fernandez J, Saliba F, Sy E, Jalan R, et al. Dynamic prognostication in critically ill cirrhotic patients with multiorgan failure in ICUs in Europe and North America: a multicenter analysis. Crit Care Med. 2018;46(11):1783–91.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jody C. Olson .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Olson, J.C. (2020). Intensive Care Management of Patients with Cirrhosis. In: Rahimi, R. (eds) The Critically Ill Cirrhotic Patient. Springer, Cham. https://doi.org/10.1007/978-3-030-24490-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-24490-3_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-24489-7

  • Online ISBN: 978-3-030-24490-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics